Derek Archila
Stock Analyst at Wells Fargo
(4.45)
# 310
Out of 5,147 analysts
232
Total ratings
56.69%
Success rate
17.81%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Overweight | $1,317 → $1,247 | $766.92 | +62.60% | 16 | Feb 27, 2026 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $114 → $110 | $39.07 | +181.55% | 4 | Feb 27, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $145 → $136 | $92.73 | +46.66% | 8 | Feb 27, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $109 → $78 | $66.62 | +17.08% | 2 | Feb 17, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $88 → $98 | $66.48 | +47.41% | 3 | Feb 13, 2026 | |
| INCY Incyte | Maintains: Equal-Weight | $107 → $101 | $101.27 | -0.27% | 13 | Feb 11, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $26 → $29 | $29.38 | -1.29% | 3 | Feb 3, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $30 → $29 | $15.97 | +81.59% | 8 | Jan 29, 2026 | |
| ASND Ascendis Pharma | Maintains: Overweight | $322 → $330 | $233.50 | +41.33% | 16 | Jan 20, 2026 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $29 → $26 | $20.96 | +24.05% | 14 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $479 → $376 | $332.92 | +12.94% | 2 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $30 | $17.75 | +69.01% | 9 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $14 | $13.97 | +0.21% | 6 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $39 | $29.69 | +31.36% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $33 | $8.21 | +301.95% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $116 | $91.35 | +26.98% | 10 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $25 | $13.45 | +85.87% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $27 | $5.60 | +382.14% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $18 → $28 | $29.02 | -3.51% | 5 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $13.27 | +13.04% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $81 | $55.05 | +47.14% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $30 | $44.06 | -31.91% | 4 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $6.70 | -25.37% | 12 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $10 | $2.70 | +270.37% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.96 | +4.19% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $30.09 | +26.29% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $30 | $20.47 | +46.56% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $3.32 | -39.76% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $2.39 | +109.21% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $4.56 | +228.95% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $23.29 | -39.89% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $27.73 | +62.28% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $3.35 | +497.01% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $6.49 | +177.35% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $33.66 | +473.38% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $82.77 | -50.47% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $13.80 | +1,059.42% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $20.99 | +185.85% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $8.91 | +225.48% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.19 | +4,101.68% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $21.70 | +135.02% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $13.22 | +565.66% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $21.91 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $33.86 | - | 2 | Aug 3, 2017 |
argenx SE
Feb 27, 2026
Maintains: Overweight
Price Target: $1,317 → $1,247
Current: $766.92
Upside: +62.60%
Soleno Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $114 → $110
Current: $39.07
Upside: +181.55%
Rhythm Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $145 → $136
Current: $92.73
Upside: +46.66%
Disc Medicine
Feb 17, 2026
Maintains: Overweight
Price Target: $109 → $78
Current: $66.62
Upside: +17.08%
BridgeBio Pharma
Feb 13, 2026
Maintains: Overweight
Price Target: $88 → $98
Current: $66.48
Upside: +47.41%
Incyte
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $107 → $101
Current: $101.27
Upside: -0.27%
Viridian Therapeutics
Feb 3, 2026
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $29.38
Upside: -1.29%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $30 → $29
Current: $15.97
Upside: +81.59%
Ascendis Pharma
Jan 20, 2026
Maintains: Overweight
Price Target: $322 → $330
Current: $233.50
Upside: +41.33%
Apellis Pharmaceuticals
Jan 20, 2026
Maintains: Overweight
Price Target: $29 → $26
Current: $20.96
Upside: +24.05%
Jan 20, 2026
Maintains: Equal-Weight
Price Target: $479 → $376
Current: $332.92
Upside: +12.94%
Jan 8, 2026
Maintains: Overweight
Price Target: $22 → $30
Current: $17.75
Upside: +69.01%
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $14
Current: $13.97
Upside: +0.21%
Jan 6, 2026
Maintains: Overweight
Price Target: $17 → $39
Current: $29.69
Upside: +31.36%
Dec 16, 2025
Maintains: Overweight
Price Target: $31 → $33
Current: $8.21
Upside: +301.95%
Dec 9, 2025
Maintains: Overweight
Price Target: $69 → $116
Current: $91.35
Upside: +26.98%
Dec 8, 2025
Maintains: Overweight
Price Target: $19 → $25
Current: $13.45
Upside: +85.87%
Nov 19, 2025
Maintains: Overweight
Price Target: $14 → $27
Current: $5.60
Upside: +382.14%
Nov 14, 2025
Upgrades: Overweight
Price Target: $18 → $28
Current: $29.02
Upside: -3.51%
Nov 6, 2025
Maintains: Overweight
Price Target: $16 → $15
Current: $13.27
Upside: +13.04%
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $55.05
Upside: +47.14%
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $44.06
Upside: -31.91%
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $6.70
Upside: -25.37%
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.70
Upside: +270.37%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.96
Upside: +4.19%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $30.09
Upside: +26.29%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $40 → $30
Current: $20.47
Upside: +46.56%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $3.32
Upside: -39.76%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $2.39
Upside: +109.21%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $4.56
Upside: +228.95%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $23.29
Upside: -39.89%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $27.73
Upside: +62.28%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $3.35
Upside: +497.01%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $6.49
Upside: +177.35%
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $33.66
Upside: +473.38%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $82.77
Upside: -50.47%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $13.80
Upside: +1,059.42%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $20.99
Upside: +185.85%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $8.91
Upside: +225.48%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.19
Upside: +4,101.68%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $21.70
Upside: +135.02%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $13.22
Upside: +565.66%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $21.91
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $33.86
Upside: -